Autologous T cells engineered to express an anti-CD19 chimeric antigen receptor that recognizes CD19 on malignant B cells, activating T-cell signaling to induce cytotoxic killing and cytokine release; added metabolic armoring enhances T-cell metabolic fitness, persistence, and function within the tumor microenvironment.